Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (338) Arrow Down
Filter Results: (338) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (338)
    • News  (34)
    • Research  (273)
  • Faculty Publications  (228)

Show Results For

  • All HBS Web  (338)
    • News  (34)
    • Research  (273)
  • Faculty Publications  (228)
← Page 10 of 338 Results →
  • 01 Sep 2006
  • News

Gift of Gab

then delivered a prepared talk on a topic of their choice. Subjects ranged from the pharmaceutical industry to the relative merits of cats vs. dogs, while Kim’s presentation took a humorous yet thoughtful approach to lessons learned in... View Details
Keywords: Business Schools & Computer & Management Training; Educational Services
  • 01 Jun 2012
  • News

The Power of Philanthropy

When their son Joey died of cystic fibrosis in 1986 at age 12, Kathy and Joe O’Donnell (MBA 1971) vowed to fight the disease. O’Donnell, at the time the president of the Boston Concessions Group, joined with Vertex Pharmaceuticals and the... View Details
Keywords: Health, Social Assistance; Religious, Grantmaking, Civic, Professional, and Similar Organizations; Personal Services
  • 01 Feb 2002
  • News

Health Industry Alumni Convene for Conference

and CEO of Mediconsulting, Inc., spoke about creating a better model for business collaborations between biotech and pharmaceutical firms. Said Klietmann, the conference's biotechnology chair and a lecturer in pathology at Harvard Medical... View Details
Keywords: Ambulatory Health Care Services; Health, Social Assistance
  • 08 Apr 2009
  • Research & Ideas

Clayton Christensen on Disrupting Health Care

delivered, the way we use technology, the way pharmaceuticals are developed, the way we educate medical professionals, and who performs what kinds of services. These things are all connected, and changing one piece, or plugging an... View Details
Keywords: by Deborah Blagg; Health
  • 01 Mar 2006
  • News

Using IT to Heal U.S. Health Care

Association’s conference held on campus in early November. The three-day conference included presentations by industry executives, government officials, and HBS faculty on topics ranging from trends in the biotech and pharmaceutical... View Details
Keywords: Colleges, Universities, and Professional Schools; Educational Services; Health, Social Assistance
  • 01 Jun 2009
  • Lessons from the Classroom

The Challenges of Investing in Science-Based Innovation

"Bank of America is interested in accessing innovative digital technologies that will help it redefine how banking is done," Sato says. "The bank sees this as an opportunity to fuel its continued competitive presence in a... View Details
Keywords: by Julia Hanna; Pharmaceutical; Pharmaceutical; Pharmaceutical
  • 24 Apr 2014
  • News

Giving hope and inspiration to cancer patients around the globe

Every new day is a good day for Kathryn E. Giusti (MBA 1985) since that morning in 1996 when her oncologist told her to get her affairs in order because she had a rare blood cancer, with three years to live. Leveraging her past experience as a View Details
  • 24 Apr 2014
  • News

A passion for the sea doubles the percent of ocean set aside for conservation

Ernesto Bertarelli (MBA 1993), an America’s Cup–winning sailor and avid scuba diver, understands the importance of protecting marine ecosystems. The former owner and CEO of the pharmaceutical and biotechnology company Serono has provided... View Details
  • 02 Oct 2000
  • Research & Ideas

The Dubious Logic of Global Megamergers

with their mega-deals, you can exploit that fact to improve your own competitive position. For instance, while pharmaceutical players such as Glaxo Wellcome and SmithKline Beecham have made headlines with their merger news, one large... View Details
Keywords: by Pankaj Ghemawat & Fariborz Ghadar
  • February 2006 (Revised February 2009)
  • Case

AIDS in Brazil

By: Rohit Deshpande and Ricardo Reisen de Pinho
Abbott Labs has reached an impasse with the Brazilian government in negotiations over the pricing of a new anti-AIDS drug, Kaletra. The Brazilian government threatens compulsory licensing unless Abbott drastically reduces the price of Kaletra. View Details
Keywords: Price; Government and Politics; Health Care and Treatment; Health Disorders; Rights; Negotiation; Business and Government Relations; Pharmaceutical Industry; Brazil
Citation
Educators
Purchase
Related
Deshpande, Rohit, and Ricardo Reisen de Pinho. "AIDS in Brazil." Harvard Business School Case 506-062, February 2006. (Revised February 2009.)
  • June 2020
  • Case

Breakthroughs at Blueprint Medicines

By: Richard G. Hamermesh, Kathy Giusti and Susie L. Ma
Precision medicine company Blueprint Medicines was building a successful track record for bringing drug therapies to market 40% faster than average. The company had spent $40 million dollars and two years building a compound library that became its drug development... View Details
Keywords: Precision Medicine; Cancer; Biotechnology; Drug Development; Strategy; Expansion; Science; Genetics; Information Technology; Entrepreneurship; Organizational Culture; Management; Growth and Development; Pharmaceutical Industry; United States; Cambridge; Massachusetts
Citation
Educators
Purchase
Related
Hamermesh, Richard G., Kathy Giusti, and Susie L. Ma. "Breakthroughs at Blueprint Medicines." Harvard Business School Case 820-001, June 2020.
  • 01 Sep 2020
  • Cold Call Podcast

How to Launch a New Biosciences Product: Start Small or Dive in?

Keywords: Re: Jeffrey J. Bussgang; Pharmaceutical; Biotechnology
  • November 1969 (Revised February 1973)
  • Background Note

Note on the U.S. Prescription Drug Industry, Part II

By: Hugo Uyterhoeven and Audrey T. Sproat
Keywords: Pharmaceutical Industry; United States
Citation
Find at Harvard
Related
Uyterhoeven, Hugo, and Audrey T. Sproat. "Note on the U.S. Prescription Drug Industry, Part II." Harvard Business School Background Note 370-039, November 1969. (Revised February 1973.)
  • April 1998
  • Case

Cephalon, Inc.

By: Peter Tufano
In early 1997, Cephalon, awaited an FDA panel's decision on whether its drug, Myotrophin, would be approved. If the drug was approved, the firm might need substantial additional funds to commercialize as well as to buy back rights to it (which had been sold earlier to... View Details
Keywords: Risk Management; Financing and Loans; Health Care and Treatment; Pharmaceutical Industry; United States
Citation
Educators
Purchase
Related
Tufano, Peter, Geoffrey Verter, and Markus Mullarkey. "Cephalon, Inc." Harvard Business School Case 298-116, April 1998.
  • 1996
  • Chapter

Note on New Drug Development in the United States

By: S. Thomke and A. Nimgade
Keywords: Product Development; Pharmaceutical Industry; United States
Citation
Related
Thomke, S., and A. Nimgade. "Note on New Drug Development in the United States." In Strategic Management of Technology and Innovation. 2nd ed. by R. Burgelman, M. A. Maidique, and S. C. Wheelwright. Burr Ridge, IL: Irwin/McGraw-Hill, 1996.
  • April 2017
  • Supplement

Imprimis (D)

By: Ramon Casadesus-Masanell, Karen Elterman and Marc Appel
This case is a supplement to Imprimis (A, B, & C). It describes Imprimis’s 2015 decision to develop a $1 per pill compounded alternative to Daraprim, the branded drug that had recently undergone an extreme price hike, raising its price to $750 per pill. Imprimis also... View Details
Keywords: Decision Choices and Conditions; Growth and Development Strategy; Pharmaceutical Industry; United States
Citation
Purchase
Related
Casadesus-Masanell, Ramon, Karen Elterman, and Marc Appel. "Imprimis (D)." Harvard Business School Supplement 717-498, April 2017.
  • 24 Jul 2014
  • Op-Ed

Reform Tax Law to Keep US Firms at Home

Editor's Note. Given a veritable flood over the last year of corporate "inversions"—US companies that reincoporate in other countries to take advantage of favorable tax rates and business regulations—lawmakers in Washington D.C. are debating how to respond.... View Details
Keywords: by Mihir Desai; Pharmaceutical
  • October 1987 (Revised November 1994)
  • Case

Boston Fights Drugs (A): Designing Communications Research

By: V. Kasturi Rangan
Describes in detail the research mounted by five individuals with a $20,000 budget to combat drug abuse among Boston's school-going population. Using the focus group methodology they discover that most of the current anti-drug advertising is useless. They create their... View Details
Keywords: Budgets and Budgeting; Misleading and Fraudulent Advertising; Communication Intention and Meaning; Brands and Branding; Performance Evaluation; Research and Development; Segmentation; Pharmaceutical Industry; Boston
Citation
Educators
Purchase
Related
Rangan, V. Kasturi. "Boston Fights Drugs (A): Designing Communications Research." Harvard Business School Case 588-031, October 1987. (Revised November 1994.)
  • 2023
  • Working Paper

Market Exclusivity and Innovation: Evidence From Antibiotics

By: Edward Kong and Olivia Zhao
The US incentivizes drug innovation via patents as well as market exclusivity periods awarded by the US Food and Drug Administration. We estimate the causal effects of extending market exclusivity for an important drug class: antibiotics. Using a... View Details
Keywords: Health Testing and Trials; Innovation and Invention; Motivation and Incentives; Government Administration; Government Legislation; Pharmaceutical Industry; United States
Citation
SSRN
Related
Kong, Edward, and Olivia Zhao. "Market Exclusivity and Innovation: Evidence From Antibiotics." Working Paper, December 2023.
  • March 2023 (Revised March 2024)
  • Case

The Purdue Pharma Bankruptcy: Settling the Opioid Crisis

By: Kristin Mugford, Carin-Isabel Knoop and Susan Pinckney
How to get to a fair outcome for claimants in the Purdue Pharma bankruptcy given its significant role in the U.S. opioid crisis. View Details
Keywords: Regulation; Ethics; Fairness; Insolvency and Bankruptcy; Government Legislation; Courts and Trials; Laws and Statutes; Lawsuits and Litigation; Legal Liability; Crime and Corruption; Negotiation Offer; Negotiation Participants; Negotiation Style; Product Design; Product Development; Brands and Branding; Marketing Strategy; Trust; Government and Politics; Law; Negotiation; Operations; Ownership; Marketing; Social Psychology; Health Care and Treatment; Pharmaceutical Industry; United States
Citation
Educators
Purchase
Related
Mugford, Kristin, Carin-Isabel Knoop, and Susan Pinckney. "The Purdue Pharma Bankruptcy: Settling the Opioid Crisis." Harvard Business School Case 223-060, March 2023. (Revised March 2024.)
  • ←
  • 10
  • 11
  • …
  • 16
  • 17
  • →
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College.